The CB1 cannabinoid receptor in the brain

Neurobiology of Disease

Volumn 5, Issue 6, 1998, Pages 405-416

  Howlett, Allyn C ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; BRAIN RECEPTOR; CALCIUM CHANNEL; CANNABINOID; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CYCLIC AMP; GUANINE NUCLEOTIDE BINDING PROTEIN; ICOSANOID; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; POTASSIUM CHANNEL; RECEPTOR PROTEIN; DRUG RECEPTOR; LIGAND;

ALLOSTERISM; ARTICLE; BRAIN; CARBOXY TERMINAL SEQUENCE; CONFORMATIONAL TRANSITION; DRUG RECEPTOR BINDING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; AMINO ACID SEQUENCE; ANIMAL; DRUG POTENTIATION; METABOLISM; MOLECULAR GENETICS; PROTEIN CONFORMATION; REVIEW;

ALLOSTERIC REGULATION; AMINO ACID SEQUENCE; ANIMALS; BRAIN; CANNABINOIDS; EICOSANOIDS; GTP-BINDING PROTEINS; HUMANS; INDOLES; LIGANDS; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; RECEPTORS, CANNABINOID; RECEPTORS, DRUG;

EID: 0032216738     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1006/nbdi.1998.0215     Document Type: Article

References (59)

1. Abood M. E., Martin B. R. Neurobiology of marijuana abuse. Trends Pharmacol. Sci. 13:1992;201-206.
2. Adams I. B., Ryan W., Singer M., Thomas B. F., Compton D. R., Razdan R. K., Martin B. R. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J. Pharmacol. Exp. Ther. 273:1995;1172-1181.
3. Ballesteros J. A., Weinstein H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci. 25:1995;366-428.
4. 12. Prostaglandins Leukotrienes Essent. Fatty Acids. 59:1998;111-118.
5. 1krox-24. J. Biol. Chem. 270:1995a;13973-13980.
6. 1. Biochem. J. 312:1995b;637-641.
7. Bramblett R. D., Panu A. M., Ballesteros J. A., Reggio P. H. Construction of a 3D model of the cannabinoid CB1 receptor: Determination of helix ends and helix orientation. Life Sci. 56:1995;1971-1982.
8. 1. Eur. J. Pharmacol. 336:1997;295-298.
9. Burstein S. H., Young J. K., Wright G. E. Relationship between eicosanoids and cannabinoids. Are eicosanoids cannabimimetic agents. Biochem. Pharmacol. 50:1995;1735-1742.
10. Ceresa B. P., Limbird L. E. Mutation of an aspartate residue highly conserved among G-protein-coupled receptors results in nonreciprocal disruption of α2-adrenergic receptor-G protein interactions. A negative charge at amino acid residue 79 forecasts α2A-adrenergic receptor sensitivity to allosteric modulation by monovalent cations and fully effective receptor/G protein coupling. J. Biol. Chem. 269:1994;29557-29564.
11. Childers S. R., Fleming L., Konkoy C., Marckel D., Pacheco M., Sexton T., Ward S. Opioid and cannabinoid receptor inhibition of adenylyl cyclase in brain. Ann. NY Acad. Sci. 654:1992;33-51.
12. Childers S. R., Sexton T., Roy M. B. Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem. Pharmacol. 47:1994;711-715.
13. Chin C. N., Lucas-Lenard J., Abadji V., Kendall D. A. Ligand binding and modulation of cyclic AMP levels depend on the chemical nature of residue 192 of the human cannabinoid receptor 1. J. Neurochem. 70:1998;366-373.
14. Cowsik S. M., Welsh W. J., Mukhopadhyay S., Howlett A. C. Molecular dynamics simulation of a CB1 cannabinoid receptor peptide. Am. Chem. Soc. Abstr. 1997.
15. Deutsch D. G., Omeir R., Arreaza G., Salehani D., Prestwich G. D., Huang Z., Howlett A. Methyl arachidonyl fluorophosphonate: A potent irreversible inhibitor of anandamide amidase. Biochem. Pharmacol. 53:1997;255-260.
16. Dewey W. L. Cannabinoid pharmacology. Pharmacol. Rev. 38:1986;151-178.
17. DiMarzo V., Fontana A. Anandamide, an endogenous cannabinomimetic eicosanoid: "Killing two birds with one stone." Prostaglandins Leukotrienes Essent. Fatty Acids. 53:1995;1-11.
18. Edgemond W. S., Campbell W. B., Hillard C. J. The binding of novel phenolic derivatives of anandamide to brain cannabinoid receptors. Prostaglandins Leukotrienes Essent. Fatty Acids. 52:1995;83-86.
19. Gudermann T., Nurnberg B., Schultz G. Receptors and G proteins as primary components of transmembrane signal transduction. J. Mol. Med. 73:1995;51-63.
20. Hildebrandt J. D. Role of subunit diversity in signaling by heterotrimeric G proteins. Biochem. Pharmacol. 54:1997;325-339.
21. Hollister L. E. Health aspects of cannabis. Pharmacol. Rev. 38:1986;1-20.
22. Horstman D. A., Brandon S., Wilson A. L., Guyer C. A., Cragoe E. J. Jr., Limbird L. E. An aspartate conserved among G-protein receptors confers allosteric regulation of α2-adrenergic receptors by sodium. J. Biol. Chem. 265:1990;21590-21595.
23. Houston D. B., Howlett A. C. Solubilization of the cannabinoid receptor from rat brain and its functional interaction with guanine nucleotide-binding proteins. Mol. Pharmacol. 43:1993;17-22.
24. Houston D. B., Howlett A. C. Differential receptor-G-protein coupling evoked by dissimilar cannabinoid receptor agonists. Cell. Signal. 10:1998;667-874.
25. Howlett A. C. Cannabinoid compounds and signal transduction mechanisms. Cannabinoid Receptors: Molecular Biology and Pharmacology. 1995;Academic Press, London. p. 167-204.
26. Howlett A. C., Berglund B. A., Melvin L. S. Cannabinoid receptor agonists and antagonists. Curr. Pharmaceut. Des. 1:1995;343-354.
27. Howlett A. C., Mukhopadhyay S., Cowsik S. M., Welsh W. J. A CB1 cannabinoid receptor peptide activates G proteins. Pharmacologist. 39:1997;68.
28. Howlett A. C., Qualy J. M., Khachatrian L. L. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol. Pharmacol. 29:1986;307-313.
29. Howlett A. C., Song C., Berglund B. A., Wilken G. H., Pigg J. J. Characterization of CB1 cannabinoid receptors using receptor peptide fragments and site-directed antibodies. Mol. Pharmacol. 53:1998;504-510.
30. Huffman J. W., Dai D., Martin B. R., Compton D. R. Design, synthesis and pharmacology of cannabimimetic indoles. Bioorg. Med. Chem. Lett. 4:1994;563-566.
31. Khanolkar A. D., Abadji V., Lin S., Hill W. A. G., Taha G., Abouzid K., Meng Z., Fan P., Makriyannis A. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J. Med. Chem. 39:1996;4515-4519.
32. Mackie K., Devane W. A., Hille B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol. 44:1993;498-503.
33. Mackie K., Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl. Acad. Sci. USA. 89:1992;3825-3829.
34. Matsuda L. A., Lolait S. J., Brownstein M. J., Young A. C., Bonner T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
35. Mechoulam R. The pharmacohistory ofCannabis sativa. Mechoulam R. Cannabinoids as Therapeutic Agents. 1986;1-20 CRC Press, Boca Raton.
36. Melvin L. S., Milne G. M., Johnson M. R., Wilken G. H., Howlett A. C. Structure-activity relationships defining the ACD-tricyclic cannabinoids: Cannabinoid receptor binding and analgesic activity. Drug Des. Discov. 13:1995;155-166.
37. Morris A. J., Scarlata S. Regulation of effectors by G-protein α- and βγ-subunits. Biochem. Pharmacol. 54:1997;429-435.
38. 125. J. Pharmacol. Exp. Ther. 252:1990;1108-1116.
39. Pacheco M. A., Ward S. J., Childers S. R. Identification of cannabinoid receptors in cultures of rat cerebellar granule cells. Brain Res. 603:1993;102-110.
40. Pacheco M. A., Ward S. J., Childers S. R. Differential requirements of sodium for coupling of cannabinoid receptors to adenylyl cyclase in rat brain membranes. J. Neurochem. 62:1994;1773-1782.
41. Pertwee R. G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74:1997;129-180.
42. Pinto J. C., Potie F., Rice K. C., Boring D., Johnson M. R., Evans D. M., Wilken G. H., Cantrell C. H., Howlett A. C. Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid. Mol. Pharmacol. 46:1994;516-522.
43. Reggio P. H., Greer K. V., Cox S. M. The importance of the orientation of the C9 substituent to cannabinoid activity. J. Med. Chem. 32:1989;1630-1635.
44. Reggio P. H., Panu A. M., Miles S. Characterization of a region of steric interference at the cannabinoid receptor using the active analog approach. J. Med. Chem. 36:1993;1761-1771.
45. Scheer A., Cotecchia S. Constitutively active G protein-coupled receptors: Potential mechanisms of receptor activation. J. Rec. Signal Trans. Res. 17:1997;57-73.
46. Sheskin T., Hanus L., Slager J., Vogel Z., Mechoulam R. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J. Med. Chem. 40:1997;659-667.
47. Shim J.-Y., Collantes E. R., Welsh W. J., Howlett A. C. Unified pharmacophoric model for cannabinoids and aminoalkylindoles derived from molecular superimposition of CB1 cannabinoid receptor agonists CP55244 and WIN55212-2. Parril A. L., Reddy M. R. Rational Drug Design Symposium Series. 1998a;American Chemical Society, Washington.
48. Shim J.-Y., Collantes E. R., Welsh W. J., Subramaniam B., Howlett A. C., Eissenstat M. A., Ward S. J. Three-dimensional quantitative structure-activity relationship study of the cannabimimetic (aminoalkyl)indoles using comparative molecular field analysis. J. Med. Chem. 41:1998b;4521-4532.
49. 35. Proc. Natl. Acad. Sci. USA. 92:1995;7242-7246.
50. Song C., Howlett A. C. Rat brain cannabinoid receptors are N-linked glycosylated proteins. Life Sci. 56:1995;1983-1989.
51. Song Z.-H., Bonner T. I. A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Mol. Pharmacol. 49:1996;891-896.
52. Sprang S. R. G protein mechanisms: Insights from structural analysis. Annu. Rev. Biochem. 66:1997;639-678.
53. Sunahara R. K., Dessauer C. W., Gilman A. G. Complexity and diversity of mammalian adenylate cyclases. Annu. Rev. Pharmacol. Toxicol. 36:1996;461-480.
54. 12. J. Pharmacol. Exp. Ther. 285:1998;651-658.
55. Thomas B. F., Adams I. B., Mascarella S. W., Martin B. R., Razdan R. K. Structure-activity analysis of anandamide analogs: Relationship to a cannabinoid pharmacophore. J. Med. Chem. 39:1996;471-479.
56. Tong W., Collantes E. R., Welsh W. J., Berglund B. A., Howlett A. C. Derivation of a pharmacophore model for anandamide using constrained conformational searching and comparative molecular field analysis. J. Med. Chem. 41:1998;4207-4215.
57. Xie X.-Q., Eissenstat M., Makriyannis A. Common cannabimimetic pharmacophoric requirements between aminoalkylindoles and classical cannabinoids. Life Sci. 56:1995;1963-1970.
58. Xie X.-Q., Melvin L. S., Makriyannis A. The conformational properties of the highly selective cannabinoid receptor ligand CP-55,940. J. Biol. Chem. 271:1996;10640-10647.
59. Yamada K., Rice K. C., Flippen-Anderson J. L., Eissenstat M. A., Ward S. J., Johnson M. R., Howlett A. C. (Aminoalkyl)indole isothiocyanates as potential electrophilic affinity ligands for the brain cannabinoid receptor. J. Med. Chem. 39:1996;1967-1974.